Dermapharm expands COVID-19 vaccine production capacity at ex-Merck site
The company's additional production capacities are scheduled to go into operation in May 2021
CDMO Dermapharm, a manufacturer of the Pfizer/BioNTech COVID-19 vaccine Comirnaty (formerly known as BNT162b2), says it is expanding capacity at its Reinbek, Germany site due to high demand for the shot.
Additional production capacities are now being established at Allergopharma GmbH & Co. KG, a subsidiary of Dermapharm, at Reinbek, which was formerly Merck KGaA's European allergy business before the pharma firm divested it in March 2020.
Dermapharm has said it is already begun to recruit personnel and train employees at its main production site in Brehna near Leipzig in readiness to start vaccine production as soon as possible.The additional production capacities are scheduled to go into operation in May 2021.
According to Dr Hans-Georg Feldmeier, Chairman of the Management Board of Dermapharm Holding SE, the capacities in Reinbek will "significantly exceed" its production capacities in Brehna.
Dermapharm signed a cooperation and supply agreement with BioNTech SE last September, and expanded production and special storage capacities for the formulation, as well as the aseptic filling, packaging (fill & finish) and storage of the vaccine at its mibe GmbH Arzneimittelsite site in Brehna, Germany.
The vaccine has been produced in Brehna since the beginning of October 2020.
Dermapharm said it expects the BioNTech partnership to contribute a "high double-digit million € amount" to its consolidated sales in the full year 2021.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...